Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple Dose, Randomised, Double-blind, Placebo Controlled, 2 Period Crossover Clinical Trial to Assess the Effect of Aclidinium Bromide 400 μg BID on Exercise Endurance in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01471171 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01471171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01471171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple Dose, Randomised, Double-blind, Placebo Controlled, 2 Period Crossover Clinical Trial to Assess the Effect of Aclidinium Bromide 400 μg BID on Exercise Endurance in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2011
Completion date
June 30, 2012
Enrollment
112 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)